Mortality differences in coronary patients with breast cancer treated with trimetazidine dihydrochloride: potential therapeutic implications
Yuen-Ting Cheng, Chun-Fung Sin, Edmond S. K. Ma, Stephen T. S. Lam, Bernard MY Cheung, Kai-Hang Yiu, Hung-Fat Tse, Yap-Hang Chan · 2025
Read Mortality differences in coronary patients with breast cancer treated with trimetazidine dihydrochloride: potential therapeutic implications by Yuen-Ting Cheng, Chun-Fung Sin, Edmond S. K. Ma, Stephen T. S. Lam, Bernard MY Cheung, Kai-Hang Yiu, Hung-Fat Tse, Yap-Hang Chan (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12836917.txt.
Description
Yuen-Ting Cheng and colleagues ask whether a heart drug, trimetazidine, changes survival for people who have both coronary disease and breast cancer. The drug treats angina and tweaks cell metabolism. Earlier observations linked it to lower cancer risk, but its effect once cancer exists was unknown.
The team drew on Hong Kong health records covering 1999 to 2020, comparing 169 users of the drug with over two thousand patients on nitrate therapy. Among those whose breast cancer came first, users lived longer on average. Adjusted models tied the drug to about half the death risk. The gain came mainly from non-heart causes. The authors urge care in reading these early, observational results.
Catalog record
| CREATOR | Yuen-Ting Cheng, Chun-Fung Sin, Edmond S. K. Ma, Stephen T. S. Lam, Bernard MY Cheung, Kai-Hang Yiu, Hung-Fat Tse, Yap-Hang Chan |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |